Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2020.08.31.20182428: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Informed consent was waived because the study was performed outside the context of RCT, and was retrospective in nature.
IRB: The study received the ethics approval by the Research Ethics Committee of Bellvitge University Hospital (PR145/20)Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in …SciScore for 10.1101/2020.08.31.20182428: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Informed consent was waived because the study was performed outside the context of RCT, and was retrospective in nature.
IRB: The study received the ethics approval by the Research Ethics Committee of Bellvitge University Hospital (PR145/20)Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations: The results of the present study show several limitations that must be noted. First, the study is retrospective in nature using real-world observational data, outside the context of RCT. Second, we aimed to evaluate predictors of mortality in the subset of patients receiving TCZ, with or without CS, but not to assess the efficacy of TCZ in general population with COVID-19 illness, comparing treated and untreated groups. Perhaps for this reason, the risk factors showed in our study may differ slightly from those previously recognized in other observational studies [1,30]. Third, due to the emergency situation, small variations to the standard clinical management of COVID-19 patients may not be totally ruled out as result from hospital reorganization, involving a wide spectrum of departments and physician specialists. Fourth, the number of COVID-19 patients presenting with PE and/or myocarditis may have been underestimated, since symptoms are difficult to ascertain in severe COVID-19 patients and the d-dimer and troponins are almost universally elevated. Finally, daily evolution of inflammatory parameters throughout the first days after TCZ administration was registered in a limited number of included patients, which does not allow firm conclusions to be drawn. Conclusions: As most physicians worldwide, whereas the pandemic continues to spread globally and our country is waiting for a second wave, we still tackle severe COVID-19 utilizing a variety of immunomodulat...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
